Targeting the Source of Brain Cancer

Curtana Pharmaceuticals is advancing a novel, dual-action therapy designed to halt recurrence by eradicating cancer stem cells and reversing tumor-driven immune suppression in adult and pediatric brain cancers.

Explore the Science Clinical Trials

A Clinical-Stage Innovator in Neuro-Oncology 

At Curtana Pharmaceuticals, we are driven by an urgent mission to develop life-changing therapies for patients facing the most devastating central nervous system (CNS) malignancies. Standard treatments often leave behind resilient cancer stem cells – the true source of disease recurrence. Our lead investigational therapy, CT-179, is a potent, orally available, CNS-penetrant small-molecule inhibitor targeting OLIG2 (pronounced OH-lig-two), a master transcription factor that is at the source of many types of brain cancer. By dismantling tumor architecture at its source and reawakening the body’s innate defenses, we are committed to changing the treatment paradigm. 

Taking Aim at Glioblastoma

    Adult Program

    Recurrent Glioblastoma (GBM)

    Safety, Tolerability, and MTD

    PreclinicalIND-EnablingPhase 1 ReadyPhase 1Phase 2
    Phase 1

    When GBM inevitably returns following frontline standard-of-care, the disease is exceptionally aggressive and highly resistant to further conventional treatments. In this recurrent setting, clinical options are severely limited, and median survival drops drastically to approximately 6 to 9 months. This devastating cycle of relapse is driven by a highly resilient subpopulation of cancer stem cells (CSCs) that survive initial surgical and chemoradiation interventions. These residual CSCs rely heavily on the OLIG2 transcription factor to rebuild the tumor architecture and actively suppress the immune microenvironment. Because addressing this resistance is our most immediate clinical priority, Recurrent GBM is the foundational indication for the dose-escalation phase of our ongoing OPAL Trial. By utilizing CT-179 to precisely target OLIG2, we aim to dismantle the cellular engine of recurrence, reverse tumor-driven immune evasion, and offer a powerful new therapeutic avenue for patients who have exhausted standard therapies.

    Adult Program

    Newly Diagnosed MGMT-Unmethylated GBM

    Combo with Radiation Therapy

    PreclinicalIND-EnablingPhase 1 ReadyPhase 1Phase 2
    Phase 1 Ready

    The most common and lethal primary adult brain tumor. There are approximately 30,000 to 40,000 new cases diagnosed annually across major global markets. Despite maximum surgical resection, radiation, and chemotherapy, recurrence is nearly universal. The median overall survival is approximately 14 to 16 months, with a 5-year survival rate of less than 10%. Furthermore, a significant portion of GBM patients have an MGMT-unmethylated status, rendering their tumors inherently resistant to standard chemotherapy. By targeting OLIG2, we aim to eliminate the cancer stem cells driving recurrence and sensitize tumors to radiation and immune attack.

Full Pipeline

Latest News

All News